Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(−like) therapy: A population based study of 239 patients from the Nordic lymphoma epidemiology group
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(−like) therapy : A population based study of 239 patients from the Nordic lymphoma epidemiology group. / Ludvigsen Al-Mashhadi, Ahmed; Cederleuf, Henrik; Kuhr Jensen, Rasmus; Holm Nielsen, Torsten; Bjerregård Pedersen, Martin; Bech Mortensen, Thomas; Relander, Thomas; Jerkeman, Mats; Gang, Anne Ortved; Kristensen, Anne Louise; Roost Clausen, Michael; Brown, Peter de Nully; Tang Severinsen, Marianne; Jakobsen, Lasse Hjort; Ellin, Fredrik; El-Galaly, Tarec Christoffer.
In: American Journal of Hematology, Vol. 98, No. 3, 2023, p. 388-397.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Outcome of limited-stage peripheral T-Cell lymphoma after CHOP(−like) therapy
T2 - A population based study of 239 patients from the Nordic lymphoma epidemiology group
AU - Ludvigsen Al-Mashhadi, Ahmed
AU - Cederleuf, Henrik
AU - Kuhr Jensen, Rasmus
AU - Holm Nielsen, Torsten
AU - Bjerregård Pedersen, Martin
AU - Bech Mortensen, Thomas
AU - Relander, Thomas
AU - Jerkeman, Mats
AU - Gang, Anne Ortved
AU - Kristensen, Anne Louise
AU - Roost Clausen, Michael
AU - Brown, Peter de Nully
AU - Tang Severinsen, Marianne
AU - Jakobsen, Lasse Hjort
AU - Ellin, Fredrik
AU - El-Galaly, Tarec Christoffer
N1 - Publisher Copyright: © 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.
PY - 2023
Y1 - 2023
N2 - Peripheral T-Cell Lymphomas (PTCLs) are rare, aggressive lymphomas with poor outcomes, but limited-stage disease is infrequent and not well-described. This study reports outcomes and prognostic factors in limited-stage nodal PTCLs in a binational population-based setting. Patients were identified from the Danish and Swedish lymphoma registries. Adults diagnosed with limited-stage nodal PTCL (stage I-II) and treated with CHOP(−like) therapy ±radiotherapy between 2000 and 2014 were included. Medical records were reviewed by local investigators. A total of 239 patients with a median age of 62 years were included; 67% received 6–8 cycles of CHOP(−like) therapy and 22% received 3–4 cycles, of which 59% also received radiotherapy. Autologous stem cell transplant consolidation was administered to 16% of all patients. Median follow-up was 127 months with 5-years overall survival (OS) of 58% (95% CI: 53–65) and progression-free survival (PFS) of 53% (95% CI: 47–59). In multivariable analysis, age ≥ 60 years and B-symptoms were unfavorable and ALK+ anaplastic large cell T-Cell lymphoma was favorable for survival outcomes. There was no difference in treatment-specific outcome (3–4 cycles vs. 6–8 cycles of CHOP(−like) ± radiotherapy). Low-risk patients (age < 60 without B-symptoms) had a 5-year OS of 77% (95% CI 67–89%). In the present study of limited-stage nodal PTCL, survival after curative intent chemotherapy +/− radiotherapy was inferior to that of limited-stage diffuse large B-cell lymphoma, but a subgroup of young patients without B-symptoms had very good outcomes. Treatment outcomes after 3–4 cycles versus 6–8 cycles of CHOP(−like) therapy were comparable.
AB - Peripheral T-Cell Lymphomas (PTCLs) are rare, aggressive lymphomas with poor outcomes, but limited-stage disease is infrequent and not well-described. This study reports outcomes and prognostic factors in limited-stage nodal PTCLs in a binational population-based setting. Patients were identified from the Danish and Swedish lymphoma registries. Adults diagnosed with limited-stage nodal PTCL (stage I-II) and treated with CHOP(−like) therapy ±radiotherapy between 2000 and 2014 were included. Medical records were reviewed by local investigators. A total of 239 patients with a median age of 62 years were included; 67% received 6–8 cycles of CHOP(−like) therapy and 22% received 3–4 cycles, of which 59% also received radiotherapy. Autologous stem cell transplant consolidation was administered to 16% of all patients. Median follow-up was 127 months with 5-years overall survival (OS) of 58% (95% CI: 53–65) and progression-free survival (PFS) of 53% (95% CI: 47–59). In multivariable analysis, age ≥ 60 years and B-symptoms were unfavorable and ALK+ anaplastic large cell T-Cell lymphoma was favorable for survival outcomes. There was no difference in treatment-specific outcome (3–4 cycles vs. 6–8 cycles of CHOP(−like) ± radiotherapy). Low-risk patients (age < 60 without B-symptoms) had a 5-year OS of 77% (95% CI 67–89%). In the present study of limited-stage nodal PTCL, survival after curative intent chemotherapy +/− radiotherapy was inferior to that of limited-stage diffuse large B-cell lymphoma, but a subgroup of young patients without B-symptoms had very good outcomes. Treatment outcomes after 3–4 cycles versus 6–8 cycles of CHOP(−like) therapy were comparable.
U2 - 10.1002/ajh.26803
DO - 10.1002/ajh.26803
M3 - Journal article
C2 - 36588403
AN - SCOPUS:85145386308
VL - 98
SP - 388
EP - 397
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 3
ER -
ID: 334306414